Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia

Leukemia & Lymphoma
Maria ChaudhryElisabet E Manasanch

Abstract

Multiple myeloma (MM) and Waldenström's macroglobulinemia (WM) are plasma cell disorders often treated with proteasome inhibitors. Recently, several studies evaluated carfilzomib as an initial treatment for these diseases and reported outstanding clinical outcomes. We conducted a retrospective study to report the efficacy and safety of frontline carfilzomib-based combinations in a standard of care setting. From 2014 until 2016 we identified newly diagnosed MM (n = 54) and WM (n = 6) patients treated with carfilzomib as initial therapy who met study inclusion criteria. The response rate for myeloma patients was 98% with 77% of patients undergoing upfront autologous stem cell transplant. The clinical benefit for WM was 100% with all patients having a resolution of B symptoms and anemia after treatment. Carfilzomib-based regimens are well tolerated and offer a neuropathy sparing approach with excellent responses both in newly diagnosed MM and WM making them a good choice for the frontline treatment of these diseases.

References

May 27, 2006·Blood·Fenghuang ZhanJohn D Shaughnessy
Feb 7, 2009·Blood·Pierre MorelGiampaolo Merlini
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven P TreonIrene M Ghobrial
Mar 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shirin Arastu-KapurChristopher J Kirk
Nov 16, 2012·British Journal of Haematology·Roger G OwenUNKNOWN VIth International Workshop on Waldenström macroglobulinaemia
Mar 12, 2013·Clinical Lymphoma, Myeloma & Leukemia·Elisabet E ManasanchOla Landgren
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Jan 25, 2017·Nature Reviews. Clinical Oncology·Elisabet E Manasanch, Robert Z Orlowski
Mar 1, 2017·OncoTargets and Therapy·Raphael E Steiner, Elisabet E Manasanch
Apr 6, 2017·The New England Journal of Medicine·Michel AttalUNKNOWN IFM 2009 Study

❮ Previous
Next ❯

Citations

Dec 7, 2019·Hematology·Elisabet E Manasanch
Dec 19, 2019·Cancer Metastasis Reviews·Karina Bezerra SalomãoMaría Sol Brassesco
Aug 19, 2020·Acta Haematologica·Christopher N GrimontMorie A Gertz

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.